In 2023, 55 new drugs were approved by the Center for Drug Evaluation and Research of the US Food and Drug Administration (FDA). These included 17 biopharmaceutical drugs. Rentschler Biopharma was involved in the development of four of these biopharmaceuticals, i.e. almost 25 percent of the approvals in this area....
Rentschler Biopharma, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced that the company has secured a major client for the new Rentschler Biopharma Manufacturing Center (RBMC) facility at its manufacturing site in Milford, Massachusetts. The RBMC is planned to be...
Rentschler Biopharma is pleased to announce the successful completion of the inspection of its manufacturing facility by the UK Medicines & Healthcare products Regulatory Agency. The contract development organization (CDMO) for biopharmaceuticals has received manufacturing authorization from the MHRA. The ATMP...
Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, is taking the first step in the expansion project to grow its U.S. footprint and establish a Center of Excellence in North America, putting into operation a single-use bioreactor for the 93,000...
